EAGLE PHARMACEUTICALS, INC. - Common Stock (EGRX) Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2014 to Q3 2025

Type / Class
Equity / Common Stock
Symbol
EGRX on OTC
Shares outstanding
13,080,549
Price per share
$0.50
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
12,350
Total reported value
$33,345
Share change
0
Number of holders
2
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of EAGLE PHARMACEUTICALS, INC. - Common Stock (EGRX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Nantahala Capital Management, LLC 38% 0% $14,341,106 4,945,209 0% Nantahala Capital Management, LLC 30 Jun 2025
Union Square Park Capital Management, LLC 11% $2,911,927 1,485,677 Union Square Park Partners, LP 31 Dec 2024
Nantahala Capital Partners Limited Partnership 6.2% $1,588,835 810,630 NANTAHALA CAPITAL PARTNERS LIMITED PARTNERSHIP 16 Feb 2025
J. Goldman & Co LP 5.1% $1,934,613 667,108 J. Goldman & Co LP 30 Jun 2025

As of 30 Sep 2025, 2 institutional investors reported holding 12,350 shares of EAGLE PHARMACEUTICALS, INC. - Common Stock (EGRX). This represents 0.09% of the company’s total 13,080,549 outstanding shares.

Institutional Holders of EAGLE PHARMACEUTICALS, INC. - Common Stock (EGRX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q3 12,350 $33,345 $2.70 2
2025 Q2 12,350 $35,815 $2.90 2
2025 Q1 12,350 $12,103 -$32,539 $0.98 2
2024 Q4 78,976 $38,714 -$31,377,862 $0.50 9
2024 Q3 8,556,159 $31,916,789 -$6,512,467 $3.73 64
2024 Q2 9,907,127 $55,472,621 -$2,769,706 $5.60 74
2024 Q1 10,455,755 $54,790,054 +$2,570,043 $5.24 91
2023 Q4 10,021,708 $52,411,739 -$16,507,736 $5.23 102
2023 Q3 10,333,726 $162,886,680 -$8,341,006 $15.77 106
2023 Q2 10,767,596 $209,255,589 -$25,534,292 $19.44 121
2023 Q1 11,782,526 $334,237,088 +$6,369,431 $28.37 153
2022 Q4 11,558,157 $337,854,292 +$2,935,043 $29.23 152
2022 Q3 11,476,393 $303,246,716 -$16,367,643 $26.42 141
2022 Q2 11,608,596 $515,754,776 +$21,309,292 $44.43 157
2022 Q1 11,218,058 $555,064,605 -$3,379,103 $49.49 157
2021 Q4 11,262,141 $573,200,097 -$47,669,318 $50.92 161
2021 Q3 11,827,478 $659,535,787 -$11,267,302 $55.78 150
2021 Q2 12,049,241 $515,950,498 -$4,645,556 $42.80 139
2021 Q1 12,187,000 $508,354,422 -$2,904,655 $41.74 149
2020 Q4 12,322,577 $573,859,683 -$7,942,717 $46.57 159
2020 Q3 12,528,383 $532,186,860 -$18,590,729 $42.48 166
2020 Q2 12,979,990 $622,793,103 -$13,107,477 $47.98 159
2020 Q1 13,275,863 $611,072,914 -$10,250,719 $46.00 165
2019 Q4 13,231,941 $794,836,171 +$5,696,958 $60.08 174
2019 Q3 13,181,435 $745,716,612 -$18,802,909 $56.57 181
2019 Q2 13,515,074 $752,386,030 +$12,861,692 $55.68 177
2019 Q1 13,360,577 $674,542,802 -$20,100,748 $50.49 176
2018 Q4 13,918,793 $560,616,838 -$101,297,221 $40.29 176
2018 Q3 15,379,145 $1,066,034,294 -$1,998,390 $69.33 185
2018 Q2 15,352,895 $1,161,660,505 -$26,723,487 $75.66 180
2018 Q1 15,793,097 $832,145,562 -$8,768,102 $52.69 170
2017 Q4 15,956,296 $852,479,241 +$1,040,360 $53.42 164
2017 Q3 15,880,693 $946,987,852 +$8,081,339 $59.64 164
2017 Q2 15,352,064 $1,211,067,051 +$314,204,445 $78.89 170
2017 Q1 16,442,698 $1,363,355,862 +$96,123,092 $82.94 144
2016 Q4 16,455,940 $1,305,497,671 -$54,424,036 $79.34 147
2016 Q3 16,738,705 $1,171,435,380 +$53,743,461 $70.00 134
2016 Q2 17,188,595 $666,828,561 +$29,339,655 $38.79 113
2016 Q1 15,449,103 $625,431,000 -$9,309,749 $40.50 115
2015 Q4 14,913,371 $1,322,635,128 +$75,860,257 $88.67 131
2015 Q3 14,077,511 $1,042,150,999 +$47,761,024 $74.03 117
2015 Q2 13,389,522 $1,082,026,217 +$144,233,970 $80.86 119
2015 Q1 11,689,865 $489,456,000 +$142,381,225 $41.89 68
2014 Q4 9,203,739 $142,654,000 +$21,828,053 $15.50 28
2014 Q3 2,974,685 $37,573,341 +$13,805,081 $12.65 24
2014 Q2 1,739,800 $24,925,337 -$1,914,703 $14.33 27
2014 Q1 1,913,224 $24,390,000 +$24,377,000 $12.75 28